Streetbeat News

Earnings

VIGL

Vigil Neuroscience (NASDAQ:VIGL) reported Q2 losses of $(0.52) per share, a 13.33% improvement from $(0.60) per share losses in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:24 am

CCCC

C4 Therapeutics reported Q2 losses of $(0.73) per share, missing the analyst consensus estimate of $(0.69) by 5.8%. The company's quarterly sales were $2.66M, missing the estimate of $6.44M by 58.63%. However, the company's cash, cash equivalents and marketable securities of $286.7M will be sufficient to fund planned operating expenses and capital expenditures into the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:22 am

NRG

NRG Energy has reaffirmed its guidance for Adjusted EBITDA, Operating Cash Flow, and Free Cash Flow before Growth (FCFbG) for the year 2023.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:22 am

IRWD

Ironwood Pharmaceuticals has increased its FY23 revenue outlook from $420M-$435M to $435M-$450M, surpassing the $427.88M estimate. The company also expects U.S. LINZESS net sales growth to be between 6% to 8%, up from the previous 3% to 5%. However, the adjusted EBITDA is expected to be around -$900 million, including a one-time charge of approximately $1.1 billion from the acquisition of VectivBio.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:22 am

NFE

New Fortress Energy (NASDAQ:NFE) reported Q2 adjusted earnings of $0.58 per share, beating the analyst consensus estimate of $0.56 by 3.57%. However, this is a 15.94% decrease from the same period last year. The company's quarterly sales of $561.35 million missed the analyst consensus estimate of $575.62 million by 2.48%, marking a 4.02% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:22 am

BHVN

CERE

CODI

ZBRA

Insiders at Compass Diversified (CODI), Zebra Technologies (ZBRA), Cerevel Therapeutics (CERE), and Biohaven Ltd. (BHVN) have recently made significant stock purchases. This could indicate their confidence in the companies' prospects. However, Compass Diversified and Biohaven posted losses for the second quarter, while Zebra Technologies reported a decline in net sales. Cerevel Therapeutics posted a narrower-than-expected quarterly loss.

Portfolio Pulse from Lisa Levin

August 08, 2023 | 11:21 am

BR

Broadridge Financial Solutions (BR) has projected its FY24 recurring revenue growth in constant currency to be between 6-9% and its adjusted EPS growth to be between 8-12%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:21 am

HBIO

Harvard Bioscience (NASDAQ:HBIO) reported Q2 adjusted earnings of $0.04 per share, missing the analyst consensus estimate of $0.05 by 20%. The company also reported quarterly sales of $28.80 million, missing the analyst consensus estimate of $29.50 million by 2.37%. This represents a decrease in both earnings and sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:20 am

CECO

CECO Environmental Corp. has increased its FY23 revenue guidance to $500M-$525M, up from the previous expectation of exceeding $485M. The company also updated its FY23 adjusted EBITDA forecast to be between $50M and $55M, a 25% increase at the mid-point year over year.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:19 am

STGW

Stagwell has reduced its FY23 organic net revenue growth forecast from 7.5%-10% to 0%-2%. It has also lowered its adjusted EPS forecast from $0.90-$1.05 to $0.76-$0.85, which aligns with the consensus estimate of $0.85.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 11:19 am